Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab, alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009, 24(1):153-161. doi: 10.1359/jbmr.080901.

Articles

---

June 29th 2018

Study Summary: DECIDE

Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab, alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009, 24(1):153-161. doi: 10.1359/jbmr.080901.

Latest Updated Articles

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Published: November 21st 2024 | Updated: November 23rd 2024

Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment